July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Inhibition of retinal injury-induced glial proliferation by intraocular administration of Palbociclib
Author Affiliations & Notes
  • Rachael Elaine Warrington
    Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, California, United States
  • Peter J Coffey
    Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, California, United States
  • Monte J Radeke
    Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, California, United States
  • Geoffrey P Lewis
    Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, California, United States
  • Footnotes
    Commercial Relationships   Rachael Warrington, None; Peter Coffey, None; Monte Radeke, None; Geoffrey Lewis, None
  • Footnotes
    Support  USAMRMC Grant W81XWH-16-1-0761
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4224. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rachael Elaine Warrington, Peter J Coffey, Monte J Radeke, Geoffrey P Lewis; Inhibition of retinal injury-induced glial proliferation by intraocular administration of Palbociclib. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4224.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Ocular trauma can lead to retinal detachment and subsequent vision loss, which significantly affects a person’s quality of life. At present, the only effective treatment for retinal detachment is surgical reattachment, however visual acuity may not be restored and secondary scarring known as proliferative vitreoretinopathy (PVR) may occur, leading to further visual complications. We performed a quantitative study to determine if the drug Palbociclib, a CDK4/6 inhibitor, can prevent detachment-induced glial proliferation. For comparison, we used the drug Palomid 529, an inhibitor of the Akt/mTOR pathways, previously shown to reduce proliferation and glial scarring following retinal detachment (IOVS 2009; 50: 4429-4435).

Methods : Retinal detachments were created in right eyes of New Zealand white rabbits and drugs were administered by intravitreal injection immediately after detachment. Two therapeutic concentrations were tested (Palbociclib: 24 and 120 µg; Palomid 529: 120 and 600 µg) with three replicates for each treatment. Eyes treated with vehicle alone (balanced salt solution, BSS), non-operated eyes, and non-detached regions served as controls. Animals were euthanized three days after detachment and the effect of each drug was assessed using immunohistochemistry. Significance was assessed using a Student’s T-test.

Results : In drug treated eyes, the highest dosage significantly reduced the average number of Ki67 positive Müller cells (mean±SEM: Palbociclib 0.04±0.04/mm of retina, n=3, P=0.001 and Palomid 529 2.43±1.00/mm of retina, n=3, P=0.028). In comparison, for the lower dose treatment only Palbociclib significantly decreased Ki67 labelled Müller cells (mean±SEM: Palbociclib 3.09±0.93/mm of retina, n=3, P=0.043 and Palomid 529 4.41±1.21/mm of retina, n=3) compared to vehicle injected controls (mean±SEM: BSS 6.60±1.04/mm, n=6). Neither drug prevented the increase in the number of microglia or macrophages following detachment. No adverse effects on gross retinal morphology were noted with either treatment.

Conclusions : Palbociclib, an FDA approved cancer therapeutic, is highly effective at reducing the proliferation of glial cells induced by retinal detachment. This drug, together with Palomid 529, which also suppresses glial scarring, may be good candidates for a combinatorial strategy to treat proliferative diseases such as PVR that often occurs following retinal injury.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×